

Roberto Massimo Lemoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1916786/publications.pdf>

Version: 2024-02-01

173
papers

10,589
citations

41344

49
h-index

34986

98
g-index

173
all docs

173
docs citations

173
times ranked

13240
citing authors

#	ARTICLE	IF	CITATIONS
1	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	5.2	33
2	Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product. <i>Journal of Translational Medicine</i> , 2022, 20, 14.	4.4	4
3	Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. <i>Clinical Cancer Research</i> , 2022, 28, 2753-2761.	7.0	70
4	OUP accepted manuscript. <i>Journal of Surgical Case Reports</i> , 2022, 2022, rjac047.	0.4	2
5	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	2.5	19
6	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	6.2	41
7	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	2.8	9
8	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	1.7	9
9	Feasibility of Single-Port Laparoscopic Lymph Node Biopsy for Intra-Abdominal Lymphoma: A Case Series. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2021, 31, 458-461.	1.0	2
10	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	4.1	14
11	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	2.5	56
12	Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 107, 573-582.	2.2	7
13	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. <i>Cancers</i> , 2021, 13, 34.	3.7	10
14	Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells. <i>Frontiers in Immunology</i> , 2021, 12, 753890.	4.8	3
15	Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 84-90.	1.3	7
16	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	4.1	106
17	The timing of plerixafor addition to G-CSf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 946-954.	2.4	3
18	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <i>Blood Cancer Journal</i> , 2020, 10, 96.	6.2	28

#	ARTICLE	IF	CITATIONS
19	Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. <i>Cancers</i> , 2020, 12, 3504.	3.7	30
20	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	27.0	1,407
21	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	4.6	430
22	Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. <i>Blood Advances</i> , 2020, 4, 4312-4326.	5.2	19
23	Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1695-1701.	1.3	4
24	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. <i>Haematologica</i> , 2020, 105, 2420-2431.	3.5	12
25	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	1.7	15
26	Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation. <i>Blood</i> , 2020, 136, 32-33.	1.4	1
27	Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment. <i>Blood</i> , 2020, 136, 31-31.	1.4	1
28	First Line Treatment with Hydroxyurea in Patients with Polycitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020, 136, 43-44.	1.4	0
29	Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function. <i>Journal of Translational Medicine</i> , 2019, 17, 250.	4.4	4
30	Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach. <i>British Journal of Haematology</i> , 2019, 186, e223-e225.	2.5	9
31	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 86, 106223.	0.8	7
32	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	13.7	435
33	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. <i>Cancer Medicine</i> , 2019, 8, 7567-7576.	2.8	5
34	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	1.7	3
35	Harnessing NK Cells for Cancer Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 2836.	4.8	66
36	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	1.8	10

#	ARTICLE	IF	CITATIONS
37	Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (<sc>FLAI</sc>) provides the most useful prognostic information. <i>British Journal of Haematology</i> , 2019, 184, 457-460.	2.5	13
38	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	1.7	46
39	Prompt detection of Lâ€asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas. <i>Hematological Oncology</i> , 2018, 36, 498-499.	1.7	0
40	A blastic plasmacytoid dendritic cell neoplasmâ€like phenotype identifies a subgroup of npm1â€mutated acute myeloid leukemia patients with worse prognosis. <i>American Journal of Hematology</i> , 2018, 93, E33-E35.	4.1	16
41	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cellsâ€™ vulnerability to DNA-damaging agents. <i>Haematologica</i> , 2018, 103, 80-90.	3.5	48
42	Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2501-2508.	2.0	17
43	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	2.5	7
44	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâž. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	3.4	24
45	Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4598-4598.	1.4	2
46	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. <i>Oncotarget</i> , 2018, 9, 21758-21769.	1.8	3
47	Combining flow cytometry and <i>WT1</i> assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e348-e351.	3.5	26
48	Molecular and functional characterization of CD133 + stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. <i>Cytotherapy</i> , 2017, 19, 1447-1461.	0.7	7
49	Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia. <i>Experimental Hematology</i> , 2017, 45, 10-16.	0.4	5
50	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2017, 52, 163-166.	2.4	24
51	The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. <i>Oncotarget</i> , 2017, 8, 2261-2274.	1.8	46
52	Intensive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives. <i>BioScience Trends</i> , 2017, 11, 110-114.	3.4	4
53	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. <i>Oncotarget</i> , 2017, 8, 5895-5908.	1.8	45
54	Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. <i>Oncotarget</i> , 2017, 8, 49451-49469.	1.8	49

#	ARTICLE	IF	CITATIONS
55	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	1.8	63
56	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	4.1	31
57	High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. <i>American Journal of Hematology</i> , 2016, 91, 755-762.	4.1	18
58	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1032-1040.	2.4	26
59	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016, 127, 1138-1150.	1.4	89
60	Exploiting tumor vulnerabilities: NAD ⁺ -depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 897-898.	2.4	0
61	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. <i>Clinical Cancer Research</i> , 2016, 22, 6099-6109.	7.0	19
62	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1914-1921.	7.0	110
63	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT Tj ETQq1 1 0.784314 rgBT /Ove	1.3	7
64	Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis. <i>Stem Cell Research and Therapy</i> , 2015, 6, 170.	5.5	26
65	Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	13
66	PGE ₂ -Induced IDO1 Inhibits the Capacity of Fully Mature DCs to Elicit an In Vitro Antileukemic Immune Response. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	53
67	The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	6
68	Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 846-852.	0.8	22
69	CD103 marks a subset of human CD34 ⁺ -derived langerin ⁺ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1. <i>Experimental Hematology</i> , 2015, 43, 268-276.e5.	0.4	21
70	The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. <i>Experimental Hematology</i> , 2015, 43, 974-985.e1.	0.4	24
71	Reinfusion of highly purified CD133 ⁺ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial. <i>Digestive and Liver Disease</i> , 2015, 47, 1059-1066.	0.9	22
72	Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 866-873.	0.8	11

#	ARTICLE	IF	CITATIONS
73	A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1375-1375.	1.4	1
74	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	1.6	39
75	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1026-1032.	2.0	28
76	Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 865-872.	2.4	151
77	The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells. <i>Journal of Immunology</i> , 2014, 192, 1231-1240.	0.8	72
78	Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. <i>Annals of Hematology</i> , 2014, 93, 2011-2018.	1.8	15
79	Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. <i>Annals of Hematology</i> , 2013, 92, 67-78.	1.8	43
80	Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors. <i>Experimental Hematology</i> , 2013, 41, 102-112.	0.4	19
81	Extracellular Purines Promote the Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells to the Osteogenic and Adipogenic Lineages. <i>Stem Cells and Development</i> , 2013, 22, 1097-1111.	2.1	95
82	NEW STRATEGIES FOR STEM CELL MOBILIZATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012066.	1.3	22
83	European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. <i>Bone Marrow Transplantation</i> , 2012, 47, 1046-1050.	2.4	54
84	Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. <i>Bone Marrow Transplantation</i> , 2012, 47, 1003-1005.	2.4	11
85	Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. <i>British Journal of Cancer</i> , 2012, 107, 1302-1309.	6.4	8
86	Proposed definition of "poor mobilizer" in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. <i>Bone Marrow Transplantation</i> , 2012, 47, 342-351.	2.4	156
87	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. <i>Blood</i> , 2012, 119, 217-226.	1.4	52
88	Extracellular ATP Exerts Opposite Effects on Activated and Regulatory CD4+ T Cells via Purinergic P2 Receptor Activation. <i>Journal of Immunology</i> , 2012, 189, 1303-1310.	0.8	121
89	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 314-317.	2.0	42
90	Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. <i>Bone Marrow Transplantation</i> , 2012, 47, 18-23.	2.4	20

#	ARTICLE	IF	CITATIONS
91	The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. <i>Blood</i> , 2012, 120, 2365-2375.	1.4	83
92	Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. <i>Transfusion</i> , 2012, 52, 906-914.	1.6	56
93	European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. <i>Transfusion</i> , 2012, 52, 2395-2400.	1.6	17
94	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. <i>Blood</i> , 2011, 118, 3273-3279.	1.4	356
95	Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. <i>Experimental Hematology</i> , 2011, 39, 360-374.e5.	0.4	73
96	The CD47 pathway is deregulated in human immune thrombocytopenia. <i>Experimental Hematology</i> , 2011, 39, 486-494.	0.4	21
97	Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. <i>Haematologica</i> , 2011, 96, 632-634.	3.5	27
98	The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. <i>Bone Marrow Transplantation</i> , 2011, 46, 356-363.	2.4	81
99	Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 33, 172-173.	0.7	4
100	BU/melphalan and auto-SCT in AML patients in first CR: a Gruppo Italiano Trapianto di Midollo Osseo (GITMO) retrospective study. <i>Bone Marrow Transplantation</i> , 2010, 45, 640-646.	2.4	17
101	Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. <i>Haematologica</i> , 2010, 95, 2022-2030.	3.5	95
102	The Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase (IDO1) Is Expressed by Natural Killer (NK) Cells During Cytokine-Mediated Activation. <i>Blood</i> , 2010, 116, 3894-3894.	1.4	0
103	Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. <i>Leukemia</i> , 2009, 23, 997-1000.	7.2	22
104	A novel model of CCl4-induced cirrhosis with ascites in the mouse. <i>Journal of Hepatology</i> , 2009, 51, 991-999.	3.7	100
105	The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. <i>Blood</i> , 2009, 113, 2394-2401.	1.4	237
106	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 ⁺ cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009, 114, 5191-5200.	1.4	62
107	Stem cell mobilization and collection in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 932-939.	3.7	52
108	Hematopoietic stem cell mobilization. <i>Haematologica</i> , 2008, 93, 321-324.	3.5	38

#	ARTICLE	IF	CITATIONS
109	More ADO about IDO: GVHD. <i>Blood</i> , 2008, 111, 2950-2950.	1.4	0
110	The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. <i>Blood</i> , 2007, 109, 533-542.	1.4	93
111	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 ⁺ into CD25 ⁺ T regulatory cells. <i>Blood</i> , 2007, 109, 2871-2877.	1.4	357
112	Positive Selection and Transplantation of Autologous Highly Purified CD133 ⁺ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1224-1232.	2.0	23
113	Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. <i>Digestive and Liver Disease</i> , 2007, 39, 943-951.	0.9	14
114	Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. <i>Leukemia</i> , 2007, 21, 353-355.	7.2	99
115	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VD) ⁺ -derived class I-restricted peptides. <i>British Journal of Haematology</i> , 2007, 139, 415-424.	2.5	58
116	Mobilization of Bone Marrow-Derived Hematopoietic and Endothelial Stem Cells After Orthotopic Liver Transplantation and Liver Resection. <i>Stem Cells</i> , 2006, 24, 2817-2825.	3.2	79
117	Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10 ⁺ /IL-12 ^{low/neg} accessory cells with dendritic-cell features. <i>Blood</i> , 2006, 108, 218-227.	1.4	226
118	Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow-Derived Mesenchymal Stem Cells. <i>Stem Cells</i> , 2006, 24, 454-461.	3.2	123
119	Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. <i>Experimental Hematology</i> , 2006, 34, 879-887.	0.4	88
120	The P2X7 Receptor: A Key Player in IL-1 Processing and Release. <i>Journal of Immunology</i> , 2006, 176, 3877-3883.	0.8	949
121	Impaired Dendritic Cell Immunophenotype and Function in Heart Transplant Patients Undergoing Active Cytomegalovirus Infection. <i>Transplantation</i> , 2005, 79, 219-227.	1.0	16
122	The Kinetic Status of Hematopoietic Stem Cell Subpopulations Underlies a Differential Expression of Genes Involved in Self-Renewal, Commitment, and Engraftment. <i>Stem Cells</i> , 2005, 23, 496-506.	3.2	45
123	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. <i>Experimental Hematology</i> , 2005, 33, 1521-1530.	0.4	44
124	Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. <i>Haematologica</i> , 2005, 90, 139-41.	3.5	6
125	Generation of Dendritic Cells from Positively Selected CD14 ⁺ Monocytes for Anti-tumor Immunotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 1419-1428.	1.3	40
126	Dendritic Cell Differentiation. <i>Journal of Immunology</i> , 2004, 172, 3-4.	0.8	6

#	ARTICLE	IF	CITATIONS
127	Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN- γ . <i>European Journal of Immunology</i> , 2004, 34, 1291-1302.	2.9	120
128	Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. <i>Immunology Letters</i> , 2004, 94, 11-26.	2.5	134
129	High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience. <i>Leukemia and Lymphoma</i> , 2004, 45, 321-326.	1.3	5
130	Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. <i>Blood</i> , 2004, 104, 1662-1670.	1.4	111
131	Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma. <i>Blood</i> , 2004, 104, 536-536.	1.4	12
132	Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. <i>British Journal of Haematology</i> , 2003, 121, 240-250.	2.5	43
133	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34 ⁺ human stem cells. <i>British Journal of Haematology</i> , 2003, 123, 720-729.	2.5	12
134	Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. <i>Blood</i> , 2003, 102, 1595-1600.	1.4	33
135	Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. <i>Blood</i> , 2002, 100, 230-237.	1.4	393
136	Interleukin-11 induces Th2 polarization of human CD4+ T cells. <i>Blood</i> , 2001, 97, 2758-2763.	1.4	85
137	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 391-399.	2.5	26
138	Immunotoxins Containing Recombinant Anti-CTLA-4 Single-Chain Fragment Variable Antibodies and Saporin: In Vitro Results and In Vivo Effects in an Acute Rejection Model. <i>Journal of Immunology</i> , 2001, 167, 4222-4229.	0.8	34
139	Stem Cell Factor and FLT3-Ligand Are Strictly Required to Sustain the Long-Term Expansion of Primitive CD34 ⁺ Dendritic Cell Precursors. <i>Journal of Immunology</i> , 2001, 166, 848-854.	0.8	61
140	Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2001, 27, 829-835.	2.4	7
141	In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. <i>British Journal of Haematology</i> , 2000, 110, 351-361.	2.5	65
142	Transforming growth factor β 3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis. <i>Experimental Hematology</i> , 2000, 28, 775-783.	0.4	6
143	Efficient presentation of tumor idiotype to autologous T cells by CD83+ dendritic cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients. <i>Experimental Hematology</i> , 2000, 28, 931-940.	0.4	46
144	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2273-2281.	1.6	153

#	ARTICLE	IF	CITATIONS
145	Thrombopoietin, Interleukin-11, and Early-Acting Megakaryocyte Growth Factors in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 2000, 40, 179-190.	1.3	2
146	Quantitative Evaluation of BCR-ABL Amount of Transcript Post Mobilization with G-CSF of Peripheral Blood Stem Cells from Chronic Myeloid Leukemia Patients in Cytogenetic Response. <i>Leukemia and Lymphoma</i> , 2000, 39, 113-120.	1.3	2
147	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. <i>Blood</i> , 2000, 95, 2234-2239.	1.4	2
148	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. <i>Blood</i> , 2000, 96, 355-357.	1.4	1
149	Rapid Induction of CD40 on a Subset of Granulocyte Colony-Stimulating Factor- Mobilized CD34+ Blood Cells Identifies Myeloid Committed Progenitors and Permits Selection of Nonimmunogenic CD40 ^{hi} Progenitor Cells. <i>Blood</i> , 1999, 94, 2293-2300.	1.4	30
150	Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 1999, 105, 775-779.	2.5	55
151	Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. <i>British Journal of Haematology</i> , 1999, 107, 419-428.	2.5	25
152	Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. <i>Bone Marrow Transplantation</i> , 1999, 23, 235-241.	2.4	12
153	Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. <i>Bone Marrow Transplantation</i> , 1999, 24, 467-472.	2.4	40
154	Characterization of autotransplant-related thrombocytopenia by evaluation of glycojalicin and reticulated platelets. <i>Bone Marrow Transplantation</i> , 1999, 24, 1191-1194.	2.4	7
155	Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. <i>Experimental Hematology</i> , 1999, 27, 1255-1263.	0.4	16
156	Negative selection of autologous peripheral blood stem cells. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 57-69.	1.7	3
157	T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. <i>Bone Marrow Transplantation</i> , 1998, 21, 1183-1191.	2.4	24
158	High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 22, 27-32.	2.4	54
159	Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. <i>Bone Marrow Transplantation</i> , 1998, 22, 631-637.	2.4	76
160	Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. <i>Bone Marrow Transplantation</i> , 1998, 22, 1065-1070.	2.4	21
161	Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34+ cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-HuMGDF). <i>British Journal of Haematology</i> , 1998, 100, 207-218.	2.5	9
162	Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. <i>British Journal of Haematology</i> , 1998, 101, 119-129.	2.5	9

#	ARTICLE	IF	CITATIONS
163	Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. <i>British Journal of Haematology</i> , 1998, 101, 179-188.	2.5	35
164	Generation and functional characterization of human dendritic cells derived from CD34+cells mobilized into peripheral blood: comparison with bone marrow CD34+cells. <i>British Journal of Haematology</i> , 1998, 101, 756-765.	2.5	60
165	Selection and Transplantation of Autologous Hematopoietic CD34+Cells for Patients with Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1997, 26, 1-11.	1.3	24
166	Peripheral Blood Mobilization of Hematopoietic Stem Cells: Cytokine-Mediated Regulation of Adhesive Interactions within the Hematopoietic Microenvironment. <i>Acta Haematologica</i> , 1997, 97, 90-96.	1.4	11
167	Interleukin-9 in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1997, 26, 563-573.	1.3	8
168	Cycling Status of CD34+ Cells Mobilized Into Peripheral Blood of Healthy Donors by Recombinant Human Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1997, 89, 1189-1196.	1.4	106
169	Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. <i>Blood</i> , 1996, 87, 1625-1634.	1.4	162
170	Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. <i>Blood</i> , 1996, 87, 3852-3859.	1.4	31
171	Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation for Lymphoma Patients. <i>Acta Haematologica</i> , 1996, 95, 164-170.	1.4	3
172	Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.. <i>Journal of Clinical Oncology</i> , 1996, 14, 3018-3025.	1.6	19
173	C-kit ligand (SCF) in human multiple myeloma cells. <i>Leukemia and Lymphoma</i> , 1996, 20, 457-464.	1.3	16